Home›Carbidopa Tablets

Carbidopa Tablets

Also known as: Carbidopa

Aromatic Amino Acid Decarboxylation InhibitorDOPA Decarboxylase Inhibitors

Route: Oral

11 interactions on record

Carbidopa Tablets has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Type A Or B), Rasagiline, Selegiline. Patients taking Carbidopa Tablets should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 11
Contraindicated: 3
Moderate: 8

Contraindicated (3)

Carbidopa Tablets + Monoamine Oxidase Inhibitors (Type A Or B)— Contraindicated per label contraindications section.
Carbidopa Tablets + Rasagiline— Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.
Carbidopa Tablets + Selegiline— Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Moderate (8)

Carbidopa Tablets + Butyrophenones— Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for l…
Carbidopa Tablets + Iron Salts— Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailabilit…
Carbidopa Tablets + Isoniazid— May reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.
Carbidopa Tablets + Metoclopramide— May adversely affect disease control by dopamine receptor antagonistic properties, despite increasing gastric emptying a…
Carbidopa Tablets + Papaverine— Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of…
Carbidopa Tablets + Phenothiazines— Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for l…
Carbidopa Tablets + Phenytoin— Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of…
Carbidopa Tablets + Risperidone— Dopamine D2 receptor antagonist may reduce therapeutic effects of levodopa; patients should be carefully observed for lo…

Carbidopa Tablets + Monoamine Oxidase Inhibitors (Type A Or B)⛔Contraindicated

Contraindicated per label contraindications section.

Carbidopa Tablets + Rasagiline⛔Contraindicated

Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Carbidopa Tablets + Selegiline⛔Contraindicated

Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Carbidopa Tablets + Butyrophenones🟡Moderate

Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Iron Salts🟡Moderate

Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.

Carbidopa Tablets + Isoniazid🟡Moderate

May reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Metoclopramide🟡Moderate

May adversely affect disease control by dopamine receptor antagonistic properties, despite increasing gastric emptying and levodopa bioavailability.

Carbidopa Tablets + Papaverine🟡Moderate

Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Phenothiazines🟡Moderate

Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Phenytoin🟡Moderate

Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Risperidone🟡Moderate

Dopamine D2 receptor antagonist may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.